Supplemental Table 1 Comparison of IVIG brands between IVIG-resistant and -responsive KD patients treated in 2006\*

Brand, n (% of total)	IVIC	G-resistant	IVIC	<b>G-responsive</b>	IVI	G-resistant	IVIC	<b>G-responsive</b>
(Lot #)	San Diego		San Diego		Boston		Boston	
	(n=17)		(n=30)		(n=1)		(n=24)	
IVEEGAM	13 (3	36%)	23 (6	64%)	1 (49	%)	22 (9	96%)
(VNE1A001)		4 (50%)		4 (50%)		0 (0%)		8 (100%)
(VNE1A003A)		5 (50%)		5 (50%)		1 (14%)		6 (86%)
(VNE1F003)		4 (36%)		7 (64%)		0 (0%)		8 (100%)
(Lot unknown)		0 (0%)		7 (100%)		N/A		N/A
IVEEGAM &								
Gammagard liquid, 1 (2%)								
(VNE1F003 & LE12F021	AC)	1 (100%)		0 (0%)		N/A		N/A
Gammagard liquid, 8 (17%)								
(LE12CA10AD1)		1 (50%)		1 (50%)		N/A		N/A
(LE08F005AB)		0 (0%)		4 (100%)		N/A		N/A
(LE12F003AA/LE12F017	7AA)	0 (0%)		1 (100%)		N/A		N/A
(LE12F003AA)		N/A		N/A		0 (0%)		2 (100%)
(LE12F068AB)		1 (100%)		0 (0%)		N/A		N/A
Gamunex liquid, 2 (4%)								
(26N6P71, 26N7H2,		0 (0%)		1 (100%)		N/A		N/A
26N7JK1, 26N7981)								
(26N6P71, 26N6R01)		1 (100%)		0 (0%)		N/A		N/A

\* No statistical difference was found between the number of IVIG-resistant and –responsive patients receiving Iveegam versus Gammagard or Gamunex with a Fisher's Exact test (P>0.05) N/A = Not Applicable

## **Supplemental Table 2**

Comparison of echocardiogram results between IVIG-resistant and -responsive KD patients (1998-2006)

Classification	Resistant (n=60)	Responsive (n=302)	p*
of Coronary Arteries			
Normal, n (%) <sup>¶</sup>	31 (52%)	193 (64%)	NS
Dilated	20 (33%)	100 (33%)	NS
Aneurysm/ectasia	9 (15%)	9 (3%)	0.0008

<sup>¶</sup> Classification was based on the most abnormal of at least two echocardiograms per patient. The right and left anterior descending coronary arteries were classified as: Normal=z score  $\leq 2.5$  standard deviations from the mean internal diameter normalized for body surface area; Dilated = z score > 2.5 but <4.0 and returns to <2.5 within 2 month follow-up period; Aneurysm = focal or diffuse dilatation of coronary artery segment with z score >4.0.; Ectasia= z ≥ 4.0 and persists > 2 months.

NS = not significant

\*Fisher's exact test

## **Supplemental Table 3**

## Comparison of demographic and clinical characteristics between IVIG- resistant and - responsive KD patients

	Resistant (n=60)	Responsive (n=302)	р
Age in years *	2 (0.8-3.4)	2.4 (1.2-4.2)	0.061†
	(range 2mo-9yrs)	(range 2mo-14 yrs)	
Illness day at diagnosis *#	5 (4-6)	6 (5-7)	0.002†
Males, n (%)	38 (63)	184 (61)	NS‡
Ethnicity/Race, n (% of total)			NS‡
Asian, n=65 (18.0%)	9 (13.8%)**	56 (86.2%)	
Black, n=16 (4.4%)	4 (25%)	12 (75%)	
Caucasian, n=99 (27.3%)	16 (16.2%)	83 (83.8%)	
Hispanic, n=113 (31.2%)	22 (19.5%)	91 (80.5%)	
AI/Alaskan, n=1 (0.3%	0 (0%)	1 (100%)	
Hawaiian/PI, n=1 (0.3%)	0 (0%)	1 (100%)	
Mixed, n=59 (16.3%)	9 (15.3%)	50 (84.7%)	
Unknown, n=8 (2.2%)	0 (0%)	8 (100%)	

## AI, American Indian; PI, Pacific Islander

<sup>#</sup> Illness day at diagnosis: Illness Day 1 = the first day of fever.

\*Expressed as median (25<sup>th</sup>-75<sup>th</sup> percentiles)

NS = not significant, †Wilcoxon rank sum test , ‡Chi-square test

\*\* Number of patients with specified ethnicity/race who were IVIG-resistant or –responsive divided by total number of patients with that ethnicity/race